Moreover, 80%C90% of children with SSNS experience relapses. however, a more targeted rituximab treatment did not significantly increase serum albumin levels and did not significantly reduce adverse events. Rituximab might be a promising treatment for childhood refractory nephrotic syndrome; however, the long-term effects and cost-effectiveness of rituximab treatment were not fully assessed, and there were … Continue reading Moreover, 80%C90% of children with SSNS experience relapses